Pharmacotherapy for Tobacco Control in Low-Income Countries
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals wiht...
- the SELECT trial followed participants for an average of 3.4 years.
- This study specifically focused on individuals with pre-existing cardiovascular disease - meaning they had a history of heart attack, stroke, or peripheral artery disease - and obesity.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals wiht obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared too those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically meaningful, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data
the SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death occurred in 6.5% of those receiving semaglutide versus 5.8% of those receiving placebo. While the absolute risk difference is small, the statistical significance (hazard ratio 1.13, 95% confidence interval 1.01 to 1.26) is noteworthy. Furthermore, the study reported a higher incidence of kidney disease progression in the semaglutide group.
| Outcome | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| MACE (Myocardial Infarction, Stroke, or CV Death) | 6.5 | 5.8 |
| Kidney disease Progression | 5.7 | 4.1 |
| Pancreatitis | 1.0 | 0.5 |
Who is Affected? Understanding the Risk Profile
This study specifically focused on individuals with pre-existing cardiovascular disease – meaning they had a history of heart attack, stroke, or peripheral artery disease – and obesity. The results do not necessarily apply to individuals using semaglutide for weight loss who do not have established cardiovascular issues. Though, it does highlight the importance of careful patient selection and risk assessment before initiating treatment with semaglutide, particularly in vulnerable populations. Individuals with multiple cardiovascular risk factors should be monitored closely.
What Does This Mean? Implications for Patients and Physicians
The SELECT trial results necessitate a reevaluation of the risk-benefit profile of semaglutide in patients with established cardiovascular disease.Physicians should engage in thorough discussions with their patients about these findings, weighing the potential benefits of weight loss against the potential cardiovascular risks. alternative weight management strategies may need to be considered for high-risk individuals. Further research is crucial to understand the underlying mechanisms driving this increased risk and to identify potential mitigating strategies.